|
Migraine Disorders
|
0.050 |
Biomarker
|
group |
BEFREE |
Our results demonstrate that the repetitive electrical stimulation model can simulate the allodynia during the migraine chronification, and PACAP plays a role in the pathogenesis of migraine potentially via PAC1 receptor.
|
30799680 |
2019 |
|
Migraine Disorders
|
0.050 |
Biomarker
|
group |
BEFREE |
The selective increase in pituitary adenylate cyclase-activating polypeptide-related receptors suggests that the PAC1 receptor pathway is a novel target for the treatment of migraine.
|
28776455 |
2018 |
|
Migraine Disorders
|
0.050 |
AlteredExpression
|
group |
BEFREE |
The expression of PAC1 receptors and the high potency of PACAP to induce MMA vasodilation are consistent with their potential roles in the etiology of migraine.
|
22766684 |
2012 |
|
Migraine Disorders
|
0.050 |
Biomarker
|
group |
BEFREE |
We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.
|
20974589 |
2011 |
|
Migraine Disorders
|
0.050 |
Biomarker
|
group |
BEFREE |
In the present review we summarize the protective effects of PACAP in ischemia, especially in neuronal ischemic injuries, and discuss possible points to consider when developing strategies in migraine therapy interfering with the PACAP/PAC1 receptor system.
|
29500688 |
2018 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Finally, PAC-1 remains potent against vemurafenib-resistant A375VR cells in cell culture and synergizes with vemurafenib to exert antitumor effects on A375VR cell growth in vivo Collectively, our data suggest that inhibition of MAPK signaling combined with concurrent procaspase-3 activation is an effective strategy to enhance the antitumor activity of vemurafenib and mitigate the development of resistance.Mol Cancer Ther; 15(8); 1859-69.©2016 AACR.
|
27297867 |
2016 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Pac 1 binds to PI4K2A and disrupts the PKR/PI4K2A-associated lysosome complex, contributing to destabilization of cancer cell lysosomes and triggering cell death.
|
31554935 |
2020 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Therefore, the aim of the present study was to investigate expression of PACAP and its PAC1 receptor in human thyroid papillary carcinoma, the most common endocrine malignant tumor.
|
27566169 |
2016 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
A weaker immunostaining of PAC1 receptors in normal tissue and a strong density of the three PACAP/VIP receptor subclasses in cancer tissue may be related to differential expression patterns during breast tumor progression but more samples need to be studied to validate this hypothesis.
|
16019382 |
2005 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Both IL-2 vectors exerted significant tumor growth delay; however, attempts to further enhance antitumor activity of the IL-2 vectors by combining with the proapoptotic drug procaspase activating compound 1 (PAC1) were unsuccessful.
|
27151235 |
2016 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
When given to mice bearing subcutaneous or orthotopic xenograft, PAC-1 and WF-210 inhibited the tumor growth and tumor angiogenesis.
|
29269017 |
2018 |
|
Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Based on these findings a decrease or lack of the PAC1 receptor/PACAP signalling might have an influence on tumour growth and/or differentiation.
|
31788045 |
2019 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
The expression analysis of the DSCR2 gene in different human tumour derived cell lines indicates that the gene is expressed in all proliferating cell lines tested.
|
10872820 |
2000 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Finally, PAC-1 remains potent against vemurafenib-resistant A375VR cells in cell culture and synergizes with vemurafenib to exert antitumor effects on A375VR cell growth in vivo Collectively, our data suggest that inhibition of MAPK signaling combined with concurrent procaspase-3 activation is an effective strategy to enhance the antitumor activity of vemurafenib and mitigate the development of resistance.Mol Cancer Ther; 15(8); 1859-69.©2016 AACR.
|
27297867 |
2016 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Pac 1 binds to PI4K2A and disrupts the PKR/PI4K2A-associated lysosome complex, contributing to destabilization of cancer cell lysosomes and triggering cell death.
|
31554935 |
2020 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
A weaker immunostaining of PAC1 receptors in normal tissue and a strong density of the three PACAP/VIP receptor subclasses in cancer tissue may be related to differential expression patterns during breast tumor progression but more samples need to be studied to validate this hypothesis.
|
16019382 |
2005 |
|
Brain Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
While preliminary evidence supports procaspase-3 as a viable target in preclinical models, with PAC-1 demonstrating activity in rodent models and dogs with spontaneous brain tumors, the broader applicability of procaspase-3 as a target in human brain cancers, as well as the comparability of procaspase-3 expressions between differing species, requires further investigation.
|
30859090 |
2019 |
|
Brain Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
To determine the role of PACAP and PAC1-R expression on glial proliferation, two in vivo models were examined--human brain tumors of glial origin and the reactive gliosis induced by a penetrating stab wound to the mature rat brain.
|
10867818 |
2000 |
|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Staining intensity of PAC1 receptor was strong in normal tissues both in the exocrine and endocrine parts of the pancreas, the receptor staining was markedly weaker in the adenocarcinoma.
|
31788045 |
2019 |
|
Anxiety Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
The pituitary adenylate cyclase-activating peptide (PACAP) and its receptor (PAC1) are involved in stress response and anxiety.
|
23972788 |
2013 |
|
Mental disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Human genetic studies suggest that the PACAP-PAC1-VPAC2 signaling can be associated with psychiatric illness via mechanisms of not only loss-of-function, but also gain-of-function.
|
24220567 |
2013 |
|
Cognition Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Taken together, these results suggest that PACAP, acting through stimulation of PAC1 receptor, may have a therapeutic potential to counteract cognitive deficits induced in HD.
|
29526016 |
2018 |
|
Colonic Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
These data indicate that human colon tumor cells express PAC1 and are differentially coupled to intracellular signal transduction molecules.
|
14742913 |
2004 |
|
Herpes Simplex Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
The human cytomegalovirus (CMV) a sequence has significant homology to two regions, pac-1 and pac-2, within the a sequence of herpes simplex virus type 1 (HSV-1).
|
2552148 |
1989 |
|
Hypertensive disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Therefore, we investigated the expressions of VIP, the related pituitary adenylate cyclase-activating polypeptide (PACAP), and their receptors (VPAC1, VPAC2, and PAC1) in piglets with overcirculation-induced pulmonary hypertension as an early-stage PAH model.
|
19581838 |
2009 |